Objective: To evaluate the impact of olmesartan alone or combined with one to three antihypertensive drugs on 24-h blood pressure variability (BPV) and on distribution of BP reduction in a pooled individual data analysis of 10 doubleblind, randomized, ambulatory BP monitoring (ABPM) studies. Methods: ABPMs were performed before and after 6-12 weeks of treatment with placebo (n=119), active control monotherapy [n=1195, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers (DCCBs)] olmesartan monotherapy (n=1410), active control dual combination [n=79, DCCBRthiazide diuretic (TD)], olmesartan dual combination (n=637, DCCB or TD), and triple combination therapy (n=102, DCCBRTD). 24-h BPV was calculated as unweighted or weighted SD of the mean BP, and average real variability. BP control was assessed by smoothness index and treatment-on-variability index. Results: The greatest effect on 24-h systolic BPV/diastolic BPV was observed under olmesartan triple [-2.6/-1.9;-1.9/-1.3;-1.4/-1.3mmHg] and active control dual combination [-1.8/-1.4;-1.9/-1.5; 1.2/1.1 mmHg]. Smoothness indexes and treatment-on-variability indexes were significantly (P=0.0001) higher under olmesartan dual (1.53/1.22, 1.67/1.29, 2.05/1.59), olmesartan triple (2.47/1.85, 2.80/2.06, 3.64/2.67), or active control dual combination (1.70/1.26, 1.85/1.33, 2.29/1.65) than under monotherapies (control: 0.86/0.73, 0.80/0.65, 1.01/0.82; olmesartan: 1.02/0.86, 0.95/0.78, 1.23/1.00). They were also greater in patients receiving high-dose olmesartan monotherapy or high-dose olmesartan dual combination than in the corresponding low-dose group. Conclusion: Olmesartan plus a DCCB and/or a TD produces a larger, more sustained, and smoother BP reduction than placebo and monotherapies, a desirable feature for a more effective prevention of the cardiovascular consequences of uncontrolled hypertension. Keywords: Ambulatory blood pressure monitoring, arterial hypertension, blood pressure, blood pressure variability, olmesartan, smoothness index, treatment-on-variability index. sTrough-To-peak Ratio.

Omboni, S., Kario, K., Bakris, G., Parati, G. (2018). Effect of antihypertensive treatment on 24-h blood pressure variability: Pooled individual data analysis of ambulatory blood pressuremonitoring studies based on olmesartan mono or combination treatment. JOURNAL OF HYPERTENSION, 36(4), 720-733 [10.1097/HJH.0000000000001608].

Effect of antihypertensive treatment on 24-h blood pressure variability: Pooled individual data analysis of ambulatory blood pressuremonitoring studies based on olmesartan mono or combination treatment

Parati G.
2018

Abstract

Objective: To evaluate the impact of olmesartan alone or combined with one to three antihypertensive drugs on 24-h blood pressure variability (BPV) and on distribution of BP reduction in a pooled individual data analysis of 10 doubleblind, randomized, ambulatory BP monitoring (ABPM) studies. Methods: ABPMs were performed before and after 6-12 weeks of treatment with placebo (n=119), active control monotherapy [n=1195, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers (DCCBs)] olmesartan monotherapy (n=1410), active control dual combination [n=79, DCCBRthiazide diuretic (TD)], olmesartan dual combination (n=637, DCCB or TD), and triple combination therapy (n=102, DCCBRTD). 24-h BPV was calculated as unweighted or weighted SD of the mean BP, and average real variability. BP control was assessed by smoothness index and treatment-on-variability index. Results: The greatest effect on 24-h systolic BPV/diastolic BPV was observed under olmesartan triple [-2.6/-1.9;-1.9/-1.3;-1.4/-1.3mmHg] and active control dual combination [-1.8/-1.4;-1.9/-1.5; 1.2/1.1 mmHg]. Smoothness indexes and treatment-on-variability indexes were significantly (P=0.0001) higher under olmesartan dual (1.53/1.22, 1.67/1.29, 2.05/1.59), olmesartan triple (2.47/1.85, 2.80/2.06, 3.64/2.67), or active control dual combination (1.70/1.26, 1.85/1.33, 2.29/1.65) than under monotherapies (control: 0.86/0.73, 0.80/0.65, 1.01/0.82; olmesartan: 1.02/0.86, 0.95/0.78, 1.23/1.00). They were also greater in patients receiving high-dose olmesartan monotherapy or high-dose olmesartan dual combination than in the corresponding low-dose group. Conclusion: Olmesartan plus a DCCB and/or a TD produces a larger, more sustained, and smoother BP reduction than placebo and monotherapies, a desirable feature for a more effective prevention of the cardiovascular consequences of uncontrolled hypertension. Keywords: Ambulatory blood pressure monitoring, arterial hypertension, blood pressure, blood pressure variability, olmesartan, smoothness index, treatment-on-variability index. sTrough-To-peak Ratio.
Articolo in rivista - Review Essay
ambulatory blood pressure monitoring, arterial hypertension, blood pressure, blood pressure variability, olmesartan, smoothness index, treatment-on-variability index, trough-to-peak ratio
English
2018
36
4
720
733
none
Omboni, S., Kario, K., Bakris, G., Parati, G. (2018). Effect of antihypertensive treatment on 24-h blood pressure variability: Pooled individual data analysis of ambulatory blood pressuremonitoring studies based on olmesartan mono or combination treatment. JOURNAL OF HYPERTENSION, 36(4), 720-733 [10.1097/HJH.0000000000001608].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/280200
Citazioni
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
Social impact